Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion Injury
Ischemia/reperfusion injury (IRI) represents a worldwide public health issue of increasing incidence. IRI may virtually affect all organs and tissues and is associated with significant morbidity and mortality. Particularly, the duration of blood supply deprivation has been recognized as a critical f...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2015/602597 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552261558992896 |
|---|---|
| author | Pascal Rowart Pauline Erpicum Olivier Detry Laurent Weekers Céline Grégoire Chantal Lechanteur Alexandra Briquet Yves Beguin Jean-Marie Krzesinski François Jouret |
| author_facet | Pascal Rowart Pauline Erpicum Olivier Detry Laurent Weekers Céline Grégoire Chantal Lechanteur Alexandra Briquet Yves Beguin Jean-Marie Krzesinski François Jouret |
| author_sort | Pascal Rowart |
| collection | DOAJ |
| description | Ischemia/reperfusion injury (IRI) represents a worldwide public health issue of increasing incidence. IRI may virtually affect all organs and tissues and is associated with significant morbidity and mortality. Particularly, the duration of blood supply deprivation has been recognized as a critical factor in stroke, hemorrhagic shock, or myocardial infarction, as well as in solid organ transplantation (SOT). Pathophysiologically, IRI causes multiple cellular and tissular metabolic and architectural changes. Furthermore, the reperfusion of ischemic tissues induces both local and systemic inflammation. In the particular field of SOT, IRI is an unavoidable event, which conditions both short- and long-term outcomes of graft function and survival. Clinically, the treatment of patients with IRI mostly relies on supportive maneuvers since no specific target-oriented therapy has been validated thus far. In the present review, we summarize the current literature on mesenchymal stromal cells (MSC) and their potential use as cell therapy in IRI. MSC have demonstrated immunomodulatory, anti-inflammatory, and tissue repair properties in rodent studies and in preliminary clinical trials, which may open novel avenues in the management of IRI and SOT. |
| format | Article |
| id | doaj-art-d40fa02d95ac42bb98ab2d9af0035c85 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-d40fa02d95ac42bb98ab2d9af0035c852025-02-03T05:59:08ZengWileyJournal of Immunology Research2314-88612314-71562015-01-01201510.1155/2015/602597602597Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion InjuryPascal Rowart0Pauline Erpicum1Olivier Detry2Laurent Weekers3Céline Grégoire4Chantal Lechanteur5Alexandra Briquet6Yves Beguin7Jean-Marie Krzesinski8François Jouret9Division of Nephrology and Transplantation, University of Liège CHU (ULg CHU), 4000 Liège, BelgiumDivision of Nephrology and Transplantation, University of Liège CHU (ULg CHU), 4000 Liège, BelgiumLaboratory of Cardiovascular Sciences, Groupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA), University of Liège, 4000 Liège, BelgiumDivision of Nephrology and Transplantation, University of Liège CHU (ULg CHU), 4000 Liège, BelgiumLaboratory of Hematology, Groupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA), University of Liège, 4000 Liège, BelgiumLaboratory of Cell and Gene Therapy, University of Liège CHU (ULg CHU), 4000 Liège, BelgiumLaboratory of Hematology, Groupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA), University of Liège, 4000 Liège, BelgiumLaboratory of Hematology, Groupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA), University of Liège, 4000 Liège, BelgiumDivision of Nephrology and Transplantation, University of Liège CHU (ULg CHU), 4000 Liège, BelgiumDivision of Nephrology and Transplantation, University of Liège CHU (ULg CHU), 4000 Liège, BelgiumIschemia/reperfusion injury (IRI) represents a worldwide public health issue of increasing incidence. IRI may virtually affect all organs and tissues and is associated with significant morbidity and mortality. Particularly, the duration of blood supply deprivation has been recognized as a critical factor in stroke, hemorrhagic shock, or myocardial infarction, as well as in solid organ transplantation (SOT). Pathophysiologically, IRI causes multiple cellular and tissular metabolic and architectural changes. Furthermore, the reperfusion of ischemic tissues induces both local and systemic inflammation. In the particular field of SOT, IRI is an unavoidable event, which conditions both short- and long-term outcomes of graft function and survival. Clinically, the treatment of patients with IRI mostly relies on supportive maneuvers since no specific target-oriented therapy has been validated thus far. In the present review, we summarize the current literature on mesenchymal stromal cells (MSC) and their potential use as cell therapy in IRI. MSC have demonstrated immunomodulatory, anti-inflammatory, and tissue repair properties in rodent studies and in preliminary clinical trials, which may open novel avenues in the management of IRI and SOT.http://dx.doi.org/10.1155/2015/602597 |
| spellingShingle | Pascal Rowart Pauline Erpicum Olivier Detry Laurent Weekers Céline Grégoire Chantal Lechanteur Alexandra Briquet Yves Beguin Jean-Marie Krzesinski François Jouret Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion Injury Journal of Immunology Research |
| title | Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion Injury |
| title_full | Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion Injury |
| title_fullStr | Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion Injury |
| title_full_unstemmed | Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion Injury |
| title_short | Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion Injury |
| title_sort | mesenchymal stromal cell therapy in ischemia reperfusion injury |
| url | http://dx.doi.org/10.1155/2015/602597 |
| work_keys_str_mv | AT pascalrowart mesenchymalstromalcelltherapyinischemiareperfusioninjury AT paulineerpicum mesenchymalstromalcelltherapyinischemiareperfusioninjury AT olivierdetry mesenchymalstromalcelltherapyinischemiareperfusioninjury AT laurentweekers mesenchymalstromalcelltherapyinischemiareperfusioninjury AT celinegregoire mesenchymalstromalcelltherapyinischemiareperfusioninjury AT chantallechanteur mesenchymalstromalcelltherapyinischemiareperfusioninjury AT alexandrabriquet mesenchymalstromalcelltherapyinischemiareperfusioninjury AT yvesbeguin mesenchymalstromalcelltherapyinischemiareperfusioninjury AT jeanmariekrzesinski mesenchymalstromalcelltherapyinischemiareperfusioninjury AT francoisjouret mesenchymalstromalcelltherapyinischemiareperfusioninjury |